T cell-based targeted immunotherapies for patients with multiple myeloma (Q38246639)

1 September 2017

1 reference

title

T cell-based targeted immunotherapies for patients with multiple myeloma (English)

1 reference

1 September 2017

1 reference

8

Dirk Hose

1 reference

1 September 2017

12

Hartmut Goldschmidt

1 reference

1 September 2017

Lei Wang

1

1 reference

1 September 2017

Nan Jin

2

1 reference

1 September 2017

Anita Schmitt

3

1 reference

1 September 2017

Jochen Greiner

4

1 reference

1 September 2017

Georg Malcherek

5

1 reference

1 September 2017

Michael Hundemer

6

1 reference

1 September 2017

Jiju Mani

7

1 reference

1 September 2017

Marc S Raab

9

1 reference

1 September 2017

Anthony D Ho

10

1 reference

1 September 2017

Bao-An Chen

11

1 reference

1 September 2017

Michael Schmitt

13

1 reference

1 September 2017

language of work or name

English

0 references

publication date

19 September 2014

1 reference

International Journal of Cancer

1 September 2017

1 reference

1 September 2017

136

1 reference

1 September 2017

8

1 reference

1 September 2017

1751-1768

1 reference

Multiple myeloma: evolving genetic events and host interactions

1 September 2017

1 reference

Combining immunotherapy and targeted therapies in cancer treatment

21 January 2018

1 reference

Breakthrough of the year 2013. Cancer immunotherapy

21 January 2018

1 reference

Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

21 January 2018

1 reference

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

21 January 2018

1 reference

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

21 January 2018

1 reference

Identification of human tumor antigens and its implications for diagnosis and treatment of cancer

21 January 2018

1 reference

About human tumor antigens to be used in immunotherapy

21 January 2018

1 reference

Nuclear factor-kappaB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis

21 January 2018

1 reference

Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions

21 January 2018

1 reference

Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders

21 January 2018

1 reference

Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders

21 January 2018

1 reference

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).

21 January 2018

1 reference

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells

21 January 2018

1 reference

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

21 January 2018

1 reference

CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma

21 January 2018

1 reference

A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma

21 January 2018

1 reference

Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

21 January 2018

1 reference

Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma

21 January 2018

1 reference

The Wnt signaling inhibitor dickkopf-1 is required for reentry into the cell cycle of human adult stem cells from bone marrow

21 January 2018

1 reference

Functional and structural diversity of the human Dickkopf gene family

21 January 2018

1 reference

Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction

21 January 2018

1 reference

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma

21 January 2018

1 reference

The HLA-DOB gene displays limited polymorphism with only one amino acid substitution.

21 January 2018

1 reference

Right place, right time, right peptide: DO keeps DM focused

21 January 2018

1 reference

Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma

21 January 2018

1 reference

In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans

21 January 2018

1 reference

A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients

21 January 2018

1 reference

Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma

21 January 2018

1 reference

Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma

21 January 2018

1 reference

Telomerase catalytic subunit homologs from fission yeast and human

21 January 2018

1 reference

Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma

21 January 2018

1 reference

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

21 January 2018

1 reference

In vitro activation of cytotoxic T-lymphocytes by hTERT-pulsed dendritic cells

21 January 2018

1 reference

An operational definition of epigenetics

21 January 2018

1 reference

A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy

21 January 2018

1 reference

Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma.

21 January 2018

1 reference

Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma

21 January 2018

1 reference

Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

21 January 2018

1 reference

Identification of MAGE-C1 (CT-7) epitopes for T-cell therapy of multiple myeloma

21 January 2018

1 reference

Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.

21 January 2018

1 reference

Cancer specific Mucin-1 glycoforms are expressed on multiple myeloma.

21 January 2018

1 reference

Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

21 January 2018

1 reference

Directions in the immune targeting of cancer: lessons learned from the cancer-testis Ag NY-ESO-1.

21 January 2018

1 reference

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma

21 January 2018

1 reference

Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.

21 January 2018

1 reference

PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells

21 January 2018

1 reference

DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma

21 January 2018

1 reference

PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation.

21 January 2018

1 reference

Plasma cell differentiation and multiple myeloma

21 January 2018

1 reference

Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL

21 January 2018

1 reference

High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

21 January 2018

1 reference

Cellular immune responses against the cancer-testis antigen SPAN-XB in healthy donors and patients with multiple myeloma.

21 January 2018

1 reference

Control of apoptosis and mitotic spindle checkpoint by survivin

21 January 2018

1 reference

The molecular basis and potential role of survivin in cancer diagnosis and therapy

21 January 2018

1 reference

CD8+ T cells reactive to survivin antigen in patients with multiple myeloma

21 January 2018

1 reference

Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma

21 January 2018

1 reference

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis

21 January 2018

1 reference

Identification of novel myeloma-specific XBP1 peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma

21 January 2018

1 reference

Robust isolation of malignant plasma cells in multiple myeloma.

21 January 2018

1 reference

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

21 January 2018

1 reference

Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells

21 January 2018

1 reference

Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.

21 January 2018

1 reference

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma

21 January 2018

1 reference

Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.

21 January 2018

1 reference

The role of Dickkopf-1 in bone development, homeostasis, and disease

21 January 2018

1 reference

Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo

21 January 2018

1 reference

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

21 January 2018

1 reference

Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple myeloma

21 January 2018

1 reference

Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors

21 January 2018

1 reference

Large-scale identification and characterization of human genes that activate NF-kappaB and MAPK signaling pathways

21 January 2018

1 reference

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

21 January 2018

1 reference

Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.

21 January 2018

1 reference

Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24.

21 January 2018

1 reference

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

21 January 2018

1 reference

A survey of telomerase activity in human cancer

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Generation of myeloma-specific T cells using dendritic cells loaded with MUC1- and hTERT- drived nonapeptides or myeloma cell apoptotic bodies

21 January 2018

1 reference

Targeting human telomerase reverse transcriptase with recombinant lentivector is highly effective to stimulate antitumor CD8 T-cell immunity in vivo

21 January 2018

1 reference

Novel anticancer therapeutics targeting telomerase

21 January 2018

1 reference

The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research

21 January 2018

1 reference

GSK's antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development

21 January 2018

1 reference

Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy

21 January 2018

1 reference

MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin

21 January 2018

1 reference

Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes

21 January 2018

1 reference

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells

21 January 2018

1 reference

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

Expression of serologically identified tumor antigens in acute leukemias.

21 January 2018

1 reference

Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas

21 January 2018

1 reference

Cancer/testis antigens, gametogenesis and cancer

21 January 2018

1 reference

Cancer/testis antigen expression in human mesenchymal stem cells: down-regulation of SSX impairs cell migration and matrix metalloproteinase 2 expression

21 January 2018

1 reference

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

21 January 2018

1 reference

RHAMM mRNA expression in proliferating and migrating cells of the developing central nervous system

21 January 2018

1 reference

mRNA expression of leukemia-associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies

21 January 2018

1 reference

Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia

21 January 2018

1 reference

Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?

21 January 2018

1 reference

RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability

21 January 2018

1 reference

Subcellular distribution, calmodulin interaction, and mitochondrial association of the hyaluronan-binding protein RHAMM in rat brain

21 January 2018

1 reference

Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression

21 January 2018

1 reference

HA receptors: regulators of signalling to the cytoskeleton

21 January 2018

1 reference

Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis

21 January 2018

1 reference

Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity

21 January 2018

1 reference

Signaling properties of hyaluronan receptors

21 January 2018

1 reference

The Wilms tumour gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma

21 January 2018

1 reference

WT-1 is required for early kidney development

21 January 2018

1 reference

The candidate Wilms' tumour gene is involved in genitourinary development

21 January 2018

1 reference

Tissue, developmental, and tumor-specific expression of divergent transcripts in Wilms tumor

21 January 2018

1 reference

Cancer immunotherapy targeting Wilms' tumor gene WT1 product

21 January 2018

1 reference

The role of WT1 in oncogenesis: tumor suppressor or oncogene?

21 January 2018

1 reference

A clinical overview of WT1 gene mutations

21 January 2018

1 reference

WT1-mediated growth suppression of Wilms tumor cells expressing a WT1 splicing variant.

21 January 2018

1 reference

Overexpression of the Wilms' tumor gene W T1 in primary astrocytic tumors

21 January 2018

1 reference

Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth

21 January 2018

1 reference

Graft-versus-leukemia effects associated with detectable Wilms tumor-1 specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia

21 January 2018

1 reference

CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia

21 January 2018

1 reference

Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes

21 January 2018

1 reference

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

21 January 2018

1 reference

Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.

21 January 2018

1 reference

New strategies in the treatment of multiple myeloma

21 January 2018

1 reference

Risky business: target choice in adoptive cell therapy

21 January 2018

1 reference

Immunogenic targets for specific immunotherapy in multiple myeloma

21 January 2018

1 reference

Peptide-based immunotherapy for multiple myeloma: current approaches

21 January 2018

1 reference

Vascular endothelial growth factor (VEGF) gene polymorphisms may influence the efficacy of thalidomide in multiple myeloma

21 January 2018

1 reference

Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state.

21 January 2018

1 reference

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

21 January 2018

1 reference

Functionally suppressive CD8 T regulatory cells are increased in patients with multiple myeloma: a cause for immune impairment.

21 January 2018

1 reference

Dendritic-cell-based therapeutic cancer vaccines

21 January 2018

1 reference

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

21 January 2018

1 reference

Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects

21 January 2018

1 reference

Targeting multiple-myeloma-induced immune dysfunction to improve immunotherapy outcomes

21 January 2018

1 reference

Myeloid-derived suppressor cells as osteoclast progenitors: a novel target for controlling osteolytic bone metastasis

21 January 2018

1 reference

Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions

21 January 2018

1 reference

Adoptive immunotherapy for cancer or viruses

21 January 2018

1 reference

Immunotherapy using dendritic cells against multiple myeloma: how to improve?

21 January 2018

1 reference

21 January 2018

1 reference

Immunotherapy of cancer in 2012.

21 January 2018

1 reference

Regulating the regulators in cancer-immunosuppression in multiple myeloma (MM).

21 January 2018

1 reference

Microenvironmental regulation of tumor progression and metastasis

21 January 2018

1 reference

Engineering approaches to immunotherapy.

21 January 2018

1 reference

Applications of nanotechnology for immunology

21 January 2018

1 reference

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

Gene-engineered T cells for cancer therapy

21 January 2018

1 reference

Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology

21 January 2018

1 reference

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)

21 January 2018

1 reference

Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers

21 January 2018

1 reference

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

21 January 2018

1 reference

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.

21 January 2018

1 reference

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

21 January 2018

1 reference

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

Branched peptides as therapeutics

21 January 2018

1 reference

Immunogenicity of dendritic cells pulsed with MAGE3, Survivin and B-cell maturation antigen mRNA for vaccination of multiple myeloma patients

21 January 2018

1 reference

Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

21 January 2018

1 reference

Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies

21 January 2018

1 reference

Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients

21 January 2018

1 reference

Immunotherapy at Large: The road to personalized cancer vaccines

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.29190

1 reference

release_wv6a4srn5jeoflznb5lpdwzz7a

1 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/wv6a4srn5jeoflznb5lpdwzz7a

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference